Abstract
Modified vaccinia virus Ankara (MVA) is a highly attenuated and replication-deficient strain of vaccinia virus that is increasingly used as vector for expression of recombinant genes in the research laboratory and in biomedicine for vaccine development. Major benefits of MVA include the clear safety advantage compared to conventional vaccinia viruses, the longstanding experience in the genetic engineering of the virus, and the availability of established procedures for virus production at an industrial scale. MVA vectors can be handled under biosafety level 1 conditions, and a multitude of recombinant MVA vaccines has proven to be immunogenic and protective when delivering various heterologous antigens in animals and humans. In this chapter we provide convenient state-of-the-art protocols for generation, amplification, and purification of recombinant MVA viruses. Importantly, we include methodology for rigid quality control to obtain best possible vector viruses for further investigations including clinical evaluation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moss B (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93:11341–11348
Sutter G, Moss B (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89:10847–10851
Tartaglia J et al (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217–232
Acres B, Bonnefoy J-Y (2008) Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 7:889–893
Gomez CE, Najera JL, Krupa M, Esteban M (2008) The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8:97–120
Rimmelzwaan GF, Sutter G (2009) Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 8:447–454
Kennedy JS, Greenberg RN (2008) IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 8:13–24
Mackett M, Smith GL, Moss B (1984) General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 49:857–864
Cottingham MG, Gilbert SC (2010) Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. J Virol Methods 168:233–236
Domi A, Moss B (2005) Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage [lambda]-based recombination. Nat Meth 2:95–97
Wyatt LS et al (2009) Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 83:7176–7184
Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72:1031–1038
Staib C et al (2000) Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28:1137–1142
Antonis AFG et al (2007) Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 25:4818–4827
Staib C, Lowel M, Erfle V, Sutter G (2003) Improved host range selection for recombinant modified vaccinia virus Ankara. BiotechÂniques 34:694–696, 698, 700
Staib C, Drexler I, Sutter G (2004) Construction and isolation of recombinant MVA. Methods Mol Biol 269:77–100
Wong YC, Lin LC, Melo-Silva CR, Smith SA, Tscharke DC (2011) Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection. J Virol Methods 171:295–8
Renart J, Reiser J, Stark GR (1979) Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure. Proc Natl Acad Sci USA 76:3116–3120
Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354
Acknowledgments
This work was supported by the European Community (FP7 2010; VECTORIE grant No. 261466).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kremer, M., Volz, A., Kreijtz, J.H.C.M., Fux, R., Lehmann, M.H., Sutter, G. (2012). Easy and Efficient Protocols for Working with Recombinant Vaccinia Virus MVA. In: Isaacs, S. (eds) Vaccinia Virus and Poxvirology. Methods in Molecular Biology, vol 890. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-876-4_4
Download citation
DOI: https://doi.org/10.1007/978-1-61779-876-4_4
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-875-7
Online ISBN: 978-1-61779-876-4
eBook Packages: Springer Protocols